Product Pipeline

PTG-100: α4β7 Integrin Specific Oral Peptide Antagonist for IBD

Latest News

January 8, 2016

Protagonist Therapeutics Initiates Phase 1 Study with Oral Peptide PTG-100 read more

October 20, 2015

Two Poster Presentations on Oral Peptides by Protagonist Therapeutics Accepted for the Upcoming 2015 Advances in IBD – Crohn’s & Colitis Foundation’s Clinical & Research Conference read more

September 23, 2015

Protagonist Therapeutics Receives SBIR Funding for Oral IL-23 Receptor Antagonists for Treatment of Inflammatory Bowel Diseases read more

Upcoming Events

January 11-13, 2016

Biotech Showcase 2016
San Francisco, CA

April 4-6, 2016

BIO-Europe Spring
Stockholm, Sweden

April 19-21, 2016

Cambridge Healthcare Institute’s Eleventh Annual Drug Discovery Chemistry
San Diego, CA